Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYR8T5
|
|||
| Drug Name |
ION373
|
|||
| Synonyms |
Zilganersen
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Alexander disease [ICD-11: 8A44.2] | Phase 3 | [1] | |
| Company |
Ionis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glial fibrillary acidic protein messenger RNA (GFAP mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04849741) A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered Zilganersen (ION373) in Patients With Alexander Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ionis | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.